- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
COVID-19 Battle: Govt removes export ban on anti-malarial drug HCQ
"The export policy of Hydroxychloroquine API (active pharmaceutical ingredients) and its formulations from prohibited to free with immediate effect," the Directorate General of Foreign Trade (DGFT) said in a notification.
New Delhi: The government on Thursday lifted the export ban on anti-malarial drug hydroxychloroquine with immediate effect.
The government on March 25 had banned the export of the drug, which was touted as a promising medicine in the treatment of COVID-19 pandemic.
"The export policy of Hydroxychloroquine API (active pharmaceutical ingredients) and its formulations from prohibited to free with immediate effect," the Directorate General of Foreign Trade (DGFT) said in a notification.
Indian Council of Medical Research (ICMR) had also recommended the use of hydroxychloroquine for treating healthcare workers handling suspected or confirmed coronavirus cases and also the asymptomatic household contacts of the lab-confirmed cases.
US President Donald Trump had described hydroxychloroquine as a "game-changer" in the fight against COVID-19.
Although exports of this medicine was banned, India shipped this anti-malarial drug in sync with its global commitment to deal with the coronavirus pandemic.
India supplied paracetamol and hydroxychloroquine to over 120 countries in the last two months while ensuring the domestic supply, as these two medicines are in huge demand due to COVID-19.
While paracetamol is a pain reliever, hydroxychloroquine is an old and inexpensive drug used to treat malaria. India is the largest producer and exporter of the drug globally.
India manufactures 70 per cent of the world''s supply of hydroxychloroquine. Companies like Zydus Cadila and IPCA are the major manufacturers in the country, according to the Indian Pharmaceutical Alliance (IPA).
In the US market, India accounted for about 47 per cent supply of hydroxychloroquine in 2019, according to Professor at Indian Institute of Foreign Trade (IIFT) Rakesh Mohan Joshi.
In April, Indian Drug Manufacturers'' Association (IDMA) Executive Director Ashok Kumar Madan had stated that India has an annual installed capacity of around 40 tonnes of active pharmaceutical ingredients (APIs) of hydroxychloroquine.
India exported hydroxychloroquine API worth USD 1.22 billion in April-January 2019-20. During the same period exports of formulations made from hydroxycholoroquine were at USD 5.50 billion.
PDF Link: USFDA ends emergency use of hydroxychloroquine to treat Covid-19
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751